

Award Number: W81XWH-13-1-0379

TITLE: The Stromal Contribution to the Development of Resistance to New-Generation Drugs by Castration-Resistant Prostate Cancer

PRINCIPAL INVESTIGATOR: Dr. Amy Lubik

CONTRACTING ORGANIZATION: UNIVERSITY OF BRITISH COLUMBIA
Vancouver, BC Canada V6H 3Z6

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE Qevqdt'4214		2. REPORT TYPE Annual		3. DATES COVERED HEAJ] ACFHÄGJÄ] ACFI Á	
4. TITLE AND SUBTITLE The Stromal Contribution to the Development of Resistance to New-Generation Drugs by Castration-Resistant Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER ÛÎFVÜÖÈFĞÈFÈĞİİ	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) L 8f"5a m@ V_` E-Mail: alubik@prostatecentre.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Vancouver Prostate Centre/ University of British Columbia 2660 Oak St, Vancouver, BC Canada V6H 3Z6				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The project will test the hypothesis that benign tumor support (stromal) cells have a significant role in acquired resistance of a prostate tumor to hormone therapies. Based upon our preliminary data showing that primary prostate stromal cells (PrSCs) acquire a steroidogenic phenotype under the influence of a paracrine Hedgehog (Hh) signaling microenvironment, we will test whether human bone marrow stromal cells (BMSCs) likewise convert to an androgen secreting phenotype under paracrine Hh stimulation. Aim 2 will test whether Hh-primed steroidogenic BMSCs or PrSCs can adapt to acute or chronic abiraterone treatment by further increasing their expressions of steroidogenic genes and by further increasing their outputs of T and DHT. Finally, in Aim 3, I will attempt to demonstrate in cell co-culture models that Sonic Hh produced from PCa cells activates steroidogenesis in BMCs and PrSCs and test whether the addition of abiraterone to this model co-culture system further boosts production of androgen from the co-cultured stromal cells. Collectively, this work will significantly impact on our understanding of the mechanistic process leading to CRPC by showing that benign tumor support (stromal) cells within a bone metastasis have a supportive role in the development of CRPC through their ability to synthesize T and DHT upon Hh stimulation from metastatic PCa cells, and whether this adaptation can increase resistance to new generation therapies, which may lead to more productive combined therapies not only targeting steroidogenesis, but the supporting hedgehog pathway.					
15. SUBJECT TERMS Prostate Cancer, Hedgehog signaling, Hormone Therapy, Intratumoral, Steroidogenesis, Androgens, Smoothened Agonists, Benign Prostate Stromal Cells, Bone Marrow Stromal Cells, Cell Co-culture.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	FH	

Table of Contents

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Overall Project Summary	4-11
4. Key Research Accomplishments	11
5. Conclusion	11-12
6. Publications, Abstracts, and Presentations	12
7. Inventions, Patents and Licenses	12
8. Reportable Outcome	12
9. Opportunities for Training and Professional Development	13
10. Other Achievements	13
11. References	13-14
12. Appendices	N/A

1. INTRODUCTION:

Prostate cancer (PCa) is the most prevalent solid tissue malignancy in men in Western countries(1). Local disease is often curable by radiation or surgery; however, patients with advanced (metastatic) disease are treated by androgen deprivation therapy (ADT) that ablates testicular androgen synthesis that is needed for continued tumor growth(2) . Unfortunately, ADT is usually only palliative since the tumor often recurs in a state that is refractory to the low systemic androgen levels in ADT-treated patients. This phenotype, termed castrate resistant PCa (CRPC), is the main cause of mortality from the disease. Recently, we learned that progression to CRPC can be linked to acquired intratumoral steroidogenesis (IS) that supports renewed activity of the androgen receptor (AR) in tumor cells thus enabling tumor re-growth(3). While new generation of drugs (abiraterone [abi] or Enzalutamide) that target IS or renewed AR activity have shown the ability to increase survival of CRPC patients(4), most patients treated with these drugs also soon develop resistance that limits the drug's effectiveness. Resistance to the new generation drugs is thought to be due to adaptations of the tumor cells themselves that further increase IS(5). This hypothesis, though, neglects any potential contributions to IS of cancer-adjacent stromal cells that might also acquire a steroidogenic phenotype upon exposure to the Hedgehog (Hh) signaling microenvironment of an androgen deprived prostate tumor(6). *Our work is innovative in that it seeks to illuminate the steroidogenic interaction between PCa cells that produce Hh ligands (hhs) in response to androgen deprivation and the stromal cells in the tumor microenvironment at both primary and metastatic sites. Furthermore, we seek to show that tumor stromal cells, like the cancer cells, can adapt to the new prostate cancer therapeutics and contribute to resistance to these drugs.*

2. **KEYWORDS:** Prostate Cancer, Hedgehog signaling, Hormone Therapy, Intratumoral, Steroidogenesis, Androgens, Smoothed Agonists, Benign Prostate Stromal Cells, Bone Marrow Stromal Cells, Coculture.

3. OVERALL PROJECT SUMMARY:

3a. Brief overview of the Clinical Problem Addressed by the Project:

In adult males, the normal functioning of the prostate is dependent on interactions with the surrounding stromal environment, much as the development of the prostate gland is dependent on the stromal mesenchyme for proper form and function. In cancers, these interactions are interfered with, disrupting homeostasis, differentiation, and growth; sometimes evoking tumor inhibition, at other times enhancing tumor progression(7). Recent studies from our laboratory have shown that, under androgen deprived conditions, PCa cells upregulate and secrete large amounts of Sonic Hedgehog ligand (Shh), which interacts with its receptor Patched-1 (Ptch-1) on the stromal cells to initiate a signaling chain through de-repression of Smoothed (Smo) and activation of Gli2 transcription factor signaling which culminates in the activation and secretion of steroidogenic enzymes and steroids, respectively(6). These steroids can feed back to the tumor cells, which, after ADT, have hypersensitive AR(8). Stromal steroidogenesis may play a significant part in the steroid milieu of the tumor microenvironment in addition to ADT driven upregulation of the steroidogenic potential of tumor cells, which are able to synthesize steroids from adrenal precursors, such as Dehydroepiandrosterone (DHEA), or *de novo* from precursors such as cholesterol or acetate through either the classical steroidogenesis pathway, or the backdoor pathway, which bypasses testosterone (T) as an intermediate for dihydrotestosterone (DHT) (3, 9-11).

After ADT, recurrence occurs in the majority of patients (8), and often progresses to metastatic disease. For PCa, the most common site for metastasis is bone, and these metastases are a major cause of morbidity due to replacement of haematopoietic tissue with tumor and decreased bone stability(12). Bone overgrowth at metastatic sites causes pain, fracture and spinal cord compression in patients. It has already been demonstrated that bone mesenchymal cells can be differentiated into steroidogenic cells (13) by overexpression of steroidogenic factor-1 (SF), and that SF-1 is a Hh target gene in Leydig cell differentiation (14). Furthermore, enzymes for androgen production are highly expressed in bone core metastases samples (15). LNCaP cells co-cultured with BMS cells increase their output of PSA (16). Collectively, these data suggest a potential role for Hh-induced steroidogenesis in the interactions between PCa cells and the stromal cells in the bone metastatic microenvironment.

It is the focus of my project to investigate and comprehend the interactions between PCa cells which secrete Hh and the stromal cells of both the primary and bone microenvironment which become steroidogenic under the influence of Hh signaling. We are also interested in whether this interaction could facilitate resistance to new generation drugs against PCa, such as Enzalutamide or Abiraterone (abi), which target the AR or cytochrome p450 (CYP17)A1, respectively (4). By the way of the “seed and soil” paradigm for metastasis, it maybe that *Hh signaling from PCa cells causes a differentiation to a steroidogenic phenotype in the BMS cells, which then provides androgens or precursors for tumor growth and resistance to next generation drugs, such as abi.*

3b. Summary of Results

3b1. Paracrine Hedgehog Induced Prostate Stromal Cell Steroidogenesis Contributes Significantly to Tumoral Steroid Milieu (Manuscript in progress)

This related project investigates the contribution of the benign prostate stromal cells to steroidogenesis in the PCa microenvironment when stimulated with Hh pathway Smo agonist (Ag1.5 1nM) or co-cultured with Shh overexpressing LNCaP cells (LNSHH). We have demonstrated by QRT PCR and LC/MS that induction of the steroidogenic enzymes in PrSC by Hh signaling is ligand dependant, and can be inhibited once Smo agonist Ag1.5 withdrawal (Figure 1a and b). This is an important finding in consideration that, in the developing leydig cells, once steroidogenesis is initiated, it no longer requires ligand (17). Therefore, the Hh pathway is a feasible target for decreasing steroidogenesis in PCa.




Figure1: Effect of 1nM Ag1.5 on steroidogenesis in PrSC. (A) Treatment with Ag1.5 increases mRNA expression of key steroidogenesis enzymes after 48hrs; down-regulation follows 48hr withdrawal of Ag1.5. Expression was measured by $\Delta\Delta CT$ method QRT PCR and shown +SE. (B) Steroid production, with 10 μ M OH-pregnenolone precursor, by PrSC is increased by treatment with Ag1.5, with Ag1.5 necessary for continued upregulation. Steroid levels were measured by LC/MS, normalized to cell number, and expressed as fold change + SE.

Furthermore, we have discovered that, on a per cell basis, PrSC in the presence and absence of Hh agonist are generally equal to some of the most common PCa cell lines (LNCaP and 22RV1) in steroid output when fed 22-OH cholesterol, a precursor for *de novo* steroidogenesis; however, especially under the influence of Ag1.5, PrSC cells produce much more pregnenolone, the first steroid in the steroidogenesis pathway (Figure 2a). This leads us to hypothesize that pregnenolone from the Hh activated stroma may be used as a precursor for steroidogenesis in tumor cells, or that secreted steroids may be “traded” between stromal and epithelial cells. Likewise, PrSC cells produce a much greater amount of the steroids in the backdoor pathway, such as androsterone, especially with the addition of Ag1.5 (Figure 2b). We have also demonstrated much higher levels of T are produced by coculturing LNSHH cells than with parental LNCaPs or by either cell line alone when fed 30uM OH-cholesterol (Figure 3). As LC/MS experiments are economically prohibitive, these are experiments optimized in the singular, then repeated for triplicates.




Figure 2: Comparative steroid outputs of commercially available PCa cell lines to PrSC cells with and without 1nM Ag1.5 with 10 μ M OH-cholesterol as a precursor. (A) Much higher output of

pregnenolone and (B) androsterone, a key metabolite in the backdoor pathway in PrSC cells treated with Ag1.5 compared to PCa cell lines, as measured by LC/MS, normalized to cell number + SE.




Figure3: Coculture of PrSC cells with LNCaP cells or Shh overexpressing cells (LNSHH) in either mock coculture (MC)- conditioned PrSC medium transferred to LNCaP cells, or direct coculture (CC) compared to PrSC or LNCaP alone (72hr).

*OH cholesterol precursor

Finally, we have demonstrated, by LC/MS, that by blocking Hh signalling in castrate LNCaP tumours with Tak441 Smo antagonist, we can dramatically reduce the levels of T and DHT in the tumors (Figure 4). A recent publication from these same tumours showed that Tak441 only effects signalling in the surrounding stromal, and not tumour cell signaling, and inhibits tumour growth (18).

Taken together, these results demonstrate that Hh signalling between PCa and stromal cells is crucial to tumour steroidogenesis and may be an attractive therapeutic target in both local and metastatic PCa.




Figure 4: Effect of Tak441 Hh inhibitor on steroid levels in castrate LNCaP xenografts. Previous publications on these tumours showed that Tak441 has effects only on the Hh pathway in stromal cell. Tumors treated with 25mg/mg Tak441 had much lower levels of (A) T and (B) DHT. Steroid levels are normalized to tumor weight (n=3, +SE).

3b2. Simvastatin Blocks Paracrine Hedgehog Induced Prostate Stromal Cell Steroidogenesis via Multiple Avenues

Because the Shh ligand is highly lipid modified in order to be functional, requiring a cholesterol moiety for auto-catalytic cleavage to its active form, as well as a palmitoyl addition (19, 20), we investigated whether simvastatin, which blocks the 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) and therefore the rate limiting step for cholesterol synthesis, would inhibit steroidogenesis by interfering with the autocatalysis of Shh necessary for activation and secretion. We discovered, by ELISA, that simvastatin appears to increase output of Shh; however, simvastatin still prevents an increase in PrSC steroidogenesis when used in mock-co-culture (serum free medium is added to LNSHH or parental cells and let incubate in the presence or absence of 5µM

simvastatin before the conditioned medium is transferred to PrSC cells with the addition of OH-cholesterol as a precursor), as demonstrated by QRT PCR and LC/MS (Figure 5a and b). This may indicate that simvastatin interferes with Shh in alternative manner than anticipated. Additionally, we demonstrate that treating PrSC cells with simvastatin also blocks steroidogenesis induced by Ag1.5 agonist; however, this does not affect the expression levels of most of the steroidogenesis enzymes at the mRNA level.

As literature suggests that statins are associated with lower risk of PCa and metastatic PCa(21-23), part of the rationale may be that statins inhibit Hh induced steroidogenesis.




Figure 5: Effects of Simvastatin on PrSC paracrine steroidogenesis. (A) When LNCaP or LNSHH cells are incubated for 72hrs in the presence or absence of 5µM simvastatin before incubation of PrSC with conditioned medium from those cells there is a suppression of Hh induction of steroidogenesis enzyme mRNA, with the exception of HMGCR and AKR1C3, which may increase as a compensatory effect (48hr, fold change +SE). (B) Incubation of LNCaP or LNSHH cells with simvastatin before 72hr incubation of PrSC with conditioned medium blocks Hh induction of increase in steroid production (fold-change, +SE, normalized to cell number).

3b3. The Stromal Contribution to the Development of Resistance to New Generation Drugs by Castration Resistant Prostate Cancers- Data Obtained so Far

We began our experiments by purchasing commercially available bone marrow stromal cells (BMS) (Stemcell Technologies, cat# MSC-001F), which are most often used to propagate and investigate mesenchymal stem cells. For our purposes, we attempted to maintain them as BMS cells. Under therecommended conditions of 10% FBS in DMEM, these cells grew very slowly, hindering our experimental abilities. We were able to complete two key experiments with these cells.

Firstly, we investigated the effect of increasing dosages (50, 100, 200nM) of SAG Hh agonist on steroidogenesis enzyme mRNA after 48hrs (Figure 6a). At 48hrs, all 3 concentrations significantly upregulated Gli1 signaling, which is the transcriptional regulator most often associated with active Hh signaling(24); however, only at 200nM SAG did we see significant upregulation of Gli2, the transcriptional regulator on which we have demonstrated prostate stromal cell (PrSC) steroidogenesis to depend(6). We also demonstrated, by QRT PCR, significant upregulation of key steroidogenesis transcription factors SF-1 (2.6-fold, p<0.05), SREBP (1.6-fold, p<0.05), and AKR1C3 (1.35-fold, p<0.05), which converts androstenedione into T. Most importantly, we have demonstrated, by LC/MS, that exposure of commercially available BMS cells to either 100nM

SAG or 1nM Ag1.5 increases steroidogenic output when fed an 10 μ M OH-cholesterol intermediate for 72hrs (Figure 6b); SAG and Ag1.5 induced 72 and 20-fold increases in 4-pregnen-17-ol-3,20-dione (backdoor pathway), respectively, 20 and 2-fold increase in DHEA, and only SAG produced a 5.5-fold increase in T output . As treatment with 100nM SAG unexpectedly gave much higher increases in steroid output, we are in the process of determining the stability of our Ag1.5 stock.





Figure 6: Effect of of Hh agonists on 1nM Ag1.5 on steroidogenesis in commercially available BMS cells. (A) Treatment with increasing concentrations of SAG showed increased mRNA expression of key steroidogenesis enzymes after 48hrs with 200nM SAG. Expression was measured by $\Delta\Delta$ CT method QRT PCR and shown +SE. (B) Steroid production, after 72hrs, with 10 μ M OH-cholesterol precursor, was increased by treatment with both 1nM Ag1.5 and 200nM SAG. Steroid levels were measured by LC/MS, normalized to cell number, and expressed as fold change + SE.

Following the cessation of experiments with commercially available BMS cells, we undertook the lengthy process of obtaining primary bone marrow stromal cells established by our collaborator and co-mentor, Dr. Eva Corey (25) (University of Washington), dubbed BMS-EC. We allowed cells to come to 70% confluence before starving in serum free medium for 48hrs. We then treated the cells with 1nM Ag1.5 for 48hrs, and observed mRNA increases in SF-1 (1.65-fold), SREBP (1.9-fold), CYP17A1 (2.6-fold), HSD3B2 (6.8-fold), AKR1C3 (3.55-fold), and HSD17B3 (3.9-fold), with increases of Gli1 and Gli2, 2.9 and 2.5-fold, respectively. Additionally, treatment with either 1nM Ag1.5 or 100nM SAG resulted in increased steroid output after 48hrs treatment, with OH-pregnenolone precursor. The highest outputs with Ag1.5 treatment were DHEA and androstenedione, 6.5 and 3.2-fold, respectively. Treatment with SAG increased outputs of pregnenolone (2.2-fold), progesterone (2.5-fold), 17-OH progesterone (2-fold), androstenedione (3.9-fold), T (2-fold), and androsterone (4.7-fold). **Taken together, these results suggest that both commercially available BMS cells and BMS-EC cells are capable of *de novo* steroidogenesis when stimulated with Hh pathway agonists, and that this paracrine interaction with PCa cells may contribute to the favorable conditions for bone metastasis growth, making the interaction a promising target for therapeutic intervention.**

A



B




Figure 6: Effect of Hh agonists on 1nM Ag1.5 on steroidogenesis in BMS-EC cells. (A) Treatment with 1nM Ag1.5 showed increased mRNA expression of key steroidogenesis enzymes after 48hrs. Expression was measured by $\Delta\Delta\text{CT}$ method QRT PCR and shown +SE. (B) Steroid production, after 48hrs, with 10 μM OH-pregnenolone precursor, was increased by treatment with both 1nM Ag1.5 and 100nM SAG. Steroid levels were measured by LC/MS, normalized to cell number, and expressed as fold change + SE.

We expect to do the gene Chip analysis on BMS-EC cells within the next 2 month, and submit an open-access manuscript on Hh induced BMS steroidogenesis within 6 month.

3b4. Other Training Project: A Spontaneous Developmental Lineage Plasticity that Underlies the Response of Prostate Cancer Cells to Androgen Deprivation (Manuscript in progress; poster presented at AACR April 2014; presentation given at Lorne Sullivan Research Day, Vancouver, June 2014; presentation scheduled for Koc University, Istanbul, October 2014)

Androgen-dependent prostate cancer (PCa) cells can acquire features of neuroendocrine- (NE-) cells under acute androgen deprivation (AD); other neuroectodermal/mesenchymal (NE/M) cell phenotypes develop under chronic AD. We propose that a transient PCa stem-like cell mediates these transdifferentiations. We sought to reveal/maintain this stem-like state using a special “stem-transition medium” that could give rise to these complex lineages from LNCaP, CWR22r1, LAPC4, or VCaP cells after at least 14days. The medium converted these cells, en masse, to small, rounded proliferating cells that grew as 3D rosettes and spheroids. QRT and CD antigen profiling of converted LNCaP cells were most consistent with a neural/neural crest stem-like (N/NCSL) identity. N/NCSL cells fail to express androgen receptor (AR) or PSA and are significantly more resistant to hypoxia and enzalutamide than parental LNCaPs. The similarities and differences between the afore mentioned parental and stem-like cell lines were compared using microarray analysis and were found to be enriched for many of the same neural, stem-like, and developmental pathways.

Androgen-free differentiation medium allowed LNCaP N/NCSL cells to express biomarkers of neuron-, glia-, oligodendrocyte or osteocyte-like cells. Following redifferentiation in androgen-containing medium, they reverted to epithelial cells resembling parental LNCaPs but they overexpressed AR and retained expression of nestin, a neural stem marker.

LNCaP-N/NCSL cells have significantly increased tumor-initiating capability, forming tumors in nude mice from only 100 xenografted cells vs 10^6 parental cells, and are metastatic when injected intra-prostatically. They are invasive in zebrafish where we observed cells metastasizing to the brain and spine, whereas parental LNCaPs remain in the yolk sac. Likewise, when injected in the neural crest area of developing chicken embryos, only LNCaP-NCSLs migrate throughout the neural tube. Lastly, the neural crest marker BRN3A is upregulated in our stem model and immunostaining shows that increased staining is strongly correlated with patient recurrence and inversely correlated with survival.

In summary, we show that PCa(AR+) cells have a previously unsuspected developmental plasticity allowing them to revert to neural/neural crest stem-like state which may be correlated to PCa progression, therapy resistance and metastasis.

4. KEY RESEARCH ACCOMPLISHMENTS:

- Have determined that treatment of BMS cells with Hh agonists upregulates mRNA for key steroidogenesis enzymes in both the classical and backdoor pathways, in 2 different BMS cell lines.
- Have shown that treatment of two BMS cell lines with Hh agonists increases secretion of steroids in both the classical and backdoor pathways.
- Have established a co-culture system with LNCaP and LNSHH cells with PrSC which is likely easily adapted to BMS-EC.

5. CONCLUSION:

Our work has confirmed the importance of paracrine Hh signaling in PCa, as it activates/upregulates steroidogenesis in PrSC and BMS cells. We have demonstrated that exposure to Hh agonists upregulates key steroidogenesis enzyme mRNAs present in both the classical and backdoor pathways and also increase production and secretion of steroids and androgens. We have demonstrated that these benign stromal cells, when activated by Hh, readily convert very upstream precursors OH-cholesterol and OH-pregnenolone to active steroids and androgens, signifying the capacity to contribute to *de novo* steroidogenesis. In PrSC cells, upregulation of pregnenolone synthesis was most notable; however, in commercially available BMS cells, the steroid with the highest increase in output was 4-pregnen-17-ol-3,20-dione, which is a key metabolite of the backdoor pathway. In all of the stromal cell lines, we have seen upregulation of GLi2, which we had previously demonstrated to be necessary for Hh mediated steroidogenesis(6).

Importantly, we have demonstrated that blocking the stromal steroidogenesis pathways in murine tumors can inhibit T and DHT production and slow tumor growth rate (18). We have also demonstrated that Simvastatin may be a useful inhibitor of these pathways, in the context of PrSC.

Collectively, our work strongly supports that Hh signaling is involved in the progression of PCa to CRPC, at which time cells become refractory to androgen ablation by synthesizing their own

steroids(3), and that targeting of this pathway would be beneficial for tumors that involved steroidogenesis evoked by paracrine Hh signaling, as compliment to traditional targeting of the AR and steroidogenesis pathways.

Future experiments will seek further elucidate the regulation of steroidogenesis related enzymes in BMS-EC cells by Hh using gene CHIP analysis (Aim1, Major task 1, subtask 3) and to determine the Gli2 dependence of BMS-EC cells by siRNA knockdown and by transduction with constitutively active Gli2 lentiviral vector (Aim1, Major task 3, subtask 1 and 2). These findings will be compiled into an open-access research article.

Furthermore, we will use our co-culture system to illuminate the paracrine signaling between BMS cells and LNCaP cells, parental and Shh over-expressing, and the growth inducing effects of BMS cell steroidogenesis on LNCaP cells (Aim 1, Major task 5-6).

We will also test whether acute or chronic exposure of Hh-induced PrSCs or BMS cells to abiraterone or MDV3100 will further upregulate the expression of steroidogenesis enzymes (by QRT PCR) and/or output of T/ DHT by LC/MS (Specific Aim 2).

6. PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

6a. Publications: Nothing to Report

6b. Abstracts:

- 1) **Lubik A**, Adomat H, Guns ES, Buttyan R: Paracrine Hedgehog Signaling Microenvironment in ADT-treated Prostate Tumours Induces Steroidogenesis from Benign Prostate Stromal Cells. Presented by R. Buttyan at the American Urological Association (AUA) Annual Conference 2013, San Diego CA, AUA Proceedings, Abstract 502.
- 2) **Amy Anne Lubik**, Josselin Caradec, Mannan Nouri, Manuel Altamarano-Dimas, Na Li, Jennifer Bishop, Mani Moniri, Martin Gleave, Ralph Buttyan. A Spontaneous Developmental Lineage Plasticity that Underlies the Response of Prostate Cancer Cells to Androgen Deprivation. Presented at American Association of Cancer Research (AACR) Annual Conference 2014, San Diego, CA AACR Proceedings, Abstract 3017.

6c. Presentations:

- 1) **Lubik, AA**: Targeting Sonic Hedgehog Signalling with Simvastatin Blocks Prostate Stromal Cell Paracrine Steroidogenesis by Multiple Avenues. Presentation given for Vancouver Prostate Centre, Vancouver, BC, Canada, March 2014.
- 2) **Lubik, AA**: A New Model of Prostate Cancer Stem Cells and its Relevance to Castrate Resistant Prostate Cancer. Presentation given at Lorne Sullivan Research Day, Vancouver, Vancouver, BC, Canada, June 2014
- 3) **Lubik, AA**: Developmental Plasticity of Prostate Cancer and Hormone Resistance. Presentation scheduled for Koc University, Istanbul, Turkey, November 2014.

7. **INVENTIONS, PATENTS AND LICENSES**: Nothing to report

8. **REPORTABLE OUTCOMES**: Have shown that OH-cholesterol and OH-pregnenolone are readily converted to T and DHT are useful and applicable precursors for steroid conversion/

synthesis. Most laboratories use DHEA to mimic an adrenal precursor; whereas, we are more closely mimicking de novo steroidogenesis.

9. OPPORTUNITIES FOR TRAINING AND PROFESSIONAL DEVELOPMENT

- NextUp Leadership course through the Canadian Centre for Policy Alternatives and GENIUS foundation. Vancouver, BC, Canada, October 2013-May 2014.
- Presentation given for Vancouver Prostate Centre, March 2014 “Targeting Sonic Hedgehog Signalling with Simvastatin Blocks Prostate Stromal Cell Paracrine Steroidogenesis by Multiple Avenues”
- Poster presented at AACR April 2014 “A Spontaneous Developmental Lineage Plasticity that Underlies the Response of Prostate Cancer Cells to Androgen Deprivation” Amy Anne Lubik, Josselin Caradec, Mannan Nouri, Manuel Altamarano-Dimas, Na Li, Jennifer Bishop, Mani Moniri, Martin Gleave, Ralph Buttyan
- Presentation given at Lorne Sullivan Research Day, Vancouver, June 2014 “A New Model of Prostate Cancer Stem Cells and its Relevance to Castrate Resistant Prostate Cancer.”
- Presentation scheduled for Koc University, Istanbul, October 2014 “Developmental Plasticity of Prostate Cancer and Hormone Resistance.”
- Project Management Workshop through University of British Columbia Postdoctoral Association (Registered, November 2014).

10. OTHER ACHIEVEMENTS: Nothing to report.

11. REFERENCES

1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. *CA. Cancer J. Clin.*, (2010).
2. J. V. Swinnen *et al.*, Androgens, lipogenesis and prostate cancer. *The Journal of Steroid Biochemistry and Molecular Biology* 92, 273 (2004).
3. J. A. Locke *et al.*, Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. *Cancer Res.* 68, 6407 (2008).
4. J. S. de Bono *et al.*, Abiraterone and increased survival in metastatic prostate cancer. *N. Engl. J. Med.* 364, 1995 (2011).
5. C. Cai *et al.*, Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors. *Cancer Res.*, (2011).
6. E. Levina, M. Chen, R. Carkner, M. Shtutman, R. Buttyan, Paracrine hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner. *The Prostate*, (2011).
7. G. R. Cunha, S. W. Hayward, Y. Wang, W. A. Ricke, Role of the stromal microenvironment in carcinogenesis of the prostate. *Int. J. Cancer* 107, 1 (2003).
8. A. So, M. Gleave, A. Hurtado-Col, C. Nelson, Mechanisms of the development of androgen independence in prostate cancer. *World J. Urol.* 23, 1 (2005).
9. A. H. Payne, D. B. Hales, Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. *Endocr. Rev.* 25, 947 (2004).
10. A. So *et al.*, Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. *Clin. Cancer Res.* 14, 6944 (2008).

11. H. Suzuki, T. Ueda, T. Ichikawa, H. Ito, Androgen receptor involvement in the progression of prostate cancer. *Endocrine-Related Cancer* 10, 209 (2003).
12. C. J. Logothetis, S. H. Lin, Osteoblasts in prostate cancer metastasis to bone. *Nature Reviews Cancer* 5, 21 (2005).
13. S. Gondo *et al.*, Adipose tissue-derived and bone marrow-derived mesenchymal cells develop into different lineage of steroidogenic cells by forced expression of steroidogenic factor 1. *Endocrinology* 149, 4717 (2008).
14. H. H. C. Yao, W. Whoriskey, B. Capel, Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. *Genes Dev.* 16, 1433 (2002).
15. M. Stanbrough *et al.*, Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. *Cancer Res.* 66, 2815 (2006).
16. A. Mizokami *et al.*, Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. *Endocrine-Related Cancer* 16, 1139 (2009).
17. S. Y. Park, M. Tong, J. L. Jameson, Distinct roles for steroidogenic factor 1 and desert hedgehog pathways in fetal and adult Leydig cell development. *Endocrinology* 148, 3704 (2007).
18. N. Ibuki *et al.*, TAK-441, a novel investigational smoothed antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. *Int. J. Cancer* 133, 1955 (2013).
19. N. A. Riobo, Cholesterol and its derivatives in Sonic Hedgehog signaling and cancer. *Current opinion in pharmacology* 12, 736 (2012).
20. R. Y. Hardy, M. D. Resh, Identification of n-terminal residues of sonic hedgehog important for palmitoylation by hedgehog acyltransferase. *J. Biol. Chem.* 287, 42881 (2012).
21. R. J. Hamilton *et al.*, Statin medication use and the risk of biochemical recurrence after radical prostatectomy. *Cancer* 116, 3389 (2010).
22. D. J. Mener, Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature. *IUBMB Life* 62, 584 (2010).
23. I. Ortega *et al.*, Simvastatin Reduces Steroidogenesis by Inhibiting Cyp17a1 Gene Expression in Rat Ovarian Theca-Interstitial Cells 1. *Biol. Reprod.* 86, (2011).
24. M. Chen *et al.*, Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. *Cell cycle (Georgetown, Tex.)* 8, 149 (2009).
25. L. Gibson *et al.*, Disruption of bone marrow stromal cell function by etoposide. *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation* 3, 122 (1997).